| General Information | |
|---|---|
| ZINC ID | ZINC000095575719 |
| Molecular Weight (Da) | 357 |
| SMILES | CCCCCc1cc(O)c2cc(Cc3ccccc3Cl)c(=O)oc2c1 |
| Molecular Formula | C21Cl1O3 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 99.402 |
| HBA | 3 |
| HBD | 1 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 25 |
| LogP | 6.694 |
| Activity (Ki) in nM | 1949.845 |
| Polar Surface Area (PSA) | 50.44 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | - |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | - |
| Androgen receptor binding | + |
| Plasma protein binding | 1.19072628 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 16 |
| Fraction csp3 | 0.29 |
| Ilogp | 3.72 |
| Xlogp3 | 6.53 |
| Wlogp | 5.48 |
| Mlogp | 4.37 |
| Silicos-it log p | 6.53 |
| Consensus log p | 5.33 |
| Esol log s | -6.24 |
| Esol solubility (mg/ml) | 2.03E-04 |
| Esol solubility (mol/l) | 5.70E-07 |
| Esol class | Poorly sol |
| Ali log s | -7.39 |
| Ali solubility (mg/ml) | 1.47E-05 |
| Ali solubility (mol/l) | 4.11E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.54 |
| Silicos-it solubility (mg/ml) | 1.04E-06 |
| Silicos-it solubility (mol/l) | 2.91E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -3.84 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 1 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.56 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.653 |
| Logd | 4.504 |
| Logp | 6.135 |
| F (20%) | 0.862 |
| F (30%) | 0.99 |
| Mdck | 1.42E-05 |
| Ppb | 1.0035 |
| Vdss | 0.536 |
| Fu | 0.0064 |
| Cyp1a2-inh | 0.837 |
| Cyp1a2-sub | 0.585 |
| Cyp2c19-inh | 0.962 |
| Cyp2c19-sub | 0.077 |
| Cl | 4.338 |
| T12 | 0.157 |
| H-ht | 0.578 |
| Dili | 0.928 |
| Roa | 0.742 |
| Fdamdd | 0.889 |
| Skinsen | 0.675 |
| Ec | 0.003 |
| Ei | 0.82 |
| Respiratory | 0.08 |
| Bcf | 2.671 |
| Igc50 | 5.349 |
| Lc50 | 5.86 |
| Lc50dm | 5.82 |
| Nr-ar | 0.276 |
| Nr-ar-lbd | 0.006 |
| Nr-ahr | 0.774 |
| Nr-aromatase | 0.723 |
| Nr-er | 0.683 |
| Nr-er-lbd | 0.679 |
| Nr-ppar-gamma | 0.971 |
| Sr-are | 0.843 |
| Sr-atad5 | 0.056 |
| Sr-hse | 0.381 |
| Sr-mmp | 0.959 |
| Sr-p53 | 0.785 |
| Vol | 366.593 |
| Dense | 0.971 |
| Flex | 18 |
| Nstereo | 0.333 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 1 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 1 |
| Nonbiodegradable | 0 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 1 |
| Qed | 2 |
| Synth | 0.47 |
| Fsp3 | 2.33 |
| Mce-18 | 0.286 |
| Natural product-likeness | 17 |
| Alarm nmr | 0.3 |
| Bms | 1 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Rejected |
| Goldentriangle | Rejected |